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A B S T R A C T
Background
Rapid antimicrobial susceptibility tests are expected to reduce the time to clinically important results of a blood culture. This might enable
clinicians to better target therapy to a person's needs, and thereby, improve health outcomes (mortality,  length of hospital stay), and
reduce unnecessary prescribing of broad-spectrum antibiotics; thereby reducing antimicrobial resistance rates.
Objectives
To assess the eIects of rapid susceptibility testing versus standard susceptibility testing for bloodstream infections (BSIs).
Search methods
To identify studies with selected outcomes, we searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE,
LILACS, and two trials registries, between 1987 and October 2020. We used 'bloodstream infection' and 'antimicrobial susceptibility tests'
as search terms. We had no language or publication status limitations.
Selection criteria
Randomized controlled trials (RCTs) comparing rapid antimicrobial susceptibility testing (with a time-to-result of ≤ 8 hours) versus
conventional antimicrobial susceptibility testing in people with a BSI caused by any bacteria, as identified by a positive blood culture.
Data collection and analysis
Two review authors independently screened references, full-text reports of potentially relevant studies, extracted data from the studies,
and assessed risk of bias. Any disagreement was discussed and resolved with a third review author. For mortality, a dichotomous outcome,
we extracted the number of events in each arm, and presented a risk ratio (RR) with 95% confidence interval (CI) to compare  rapid
susceptibility testing to conventional methods. We used Review Manager 5.4 to meta-analyse the data. For other outcomes, which are
time-to-event outcomes (time-to-discharge from hospital, time-to-first appropriate antibiotic change), we conducted qualitative narrative
synthesis, due to heterogeneity of outcome measures.
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Main results
We included six trials, with 1638 participants. For rapid antimicrobial susceptibility testing compared to conventional methods, there was
little or no diIerence in mortality between groups (RR 1.10, 95% CI 0.82 to 1.46; 6 RCTs, 1638 participants; low-certainty evidence).  In
subgroup analysis, for rapid genotypic or molecular antimicrobial susceptibility testing compared to conventional methods, there was
little or no diIerence in mortality between groups (RR 1.02, 95% CI 0.69 to 1.49; 4 RCTs, 1074 participants; low-certainty evidence). For
phenotypic rapid susceptibility testing compared to conventional methods, there was little or no diIerence in mortality between groups
 (RR 1.37, 95% CI 0.80 to 2.35; 2 RCTs, 564 participants; low-certainty evidence).
In qualitative analysis, rapid susceptibility testing may make little or no diIerence in time-to-discharge (4 RCTs, 1165 participants; low-
certainty evidence). In qualitative analysis, rapid genotypic susceptibility testing compared to conventional testing may make little or
no diIerence in time-to-appropriate antibiotic (3 RCTs, 929 participants; low-certainty evidence). In subgroup analysis, rapid phenotypic
susceptibility testing compared to conventional testing may improve time-to-appropriate antibiotic (RR -17.29, CI -45.05 to 10.47; 2 RCTs,
564 participants; low-certainty evidence).
Authors' conclusions
The theoretical benefits of rapid susceptibility testing have not been demonstrated to directly improve mortality, time-to-discharge, or
time-to-appropriate antibiotic in these randomized studies. Future large prospective studies should be designed to focus on the most
clinically meaningful outcomes, and aim to optimize blood culture pathways.
P L A I N   L A N G U A G E   S U M M A R Y
Tests for identifying the most suitable antibiotics for a bacterial blood infection: are rapid tests better than standard tests?
What is the aim of this Cochrane Review?
People with blood infections need urgent treatment with antibiotics. Identifying the bacteria causing the infection helps ensure the right
antibiotic is given. Rapid susceptibility tests are a technology to do this quickly, and aim to improve care. We sought to evaluate whether
their use reduce deaths or shortens the illness.
Key messages
Rapid susceptibility tests to identify an appropriate antibiotic quickly for people with blood sepsis may make little to no diIerence to:
· how many people die within 30 days of diagnosis of blood sepsis;
· how long people stay in hospital;
· whether given a suitable antibiotic.
Larger studies will help determine if using rapid susceptibility tests improves these outcomes.
What was studied in this review?
Susceptibility tests are done in a laboratory, and measure whether bacteria can grow when exposed to a variety of antibiotics, to assure
that the antibiotics given are active against the organism causing the infection. The standard approach is to culture the blood samples, but
this takes up to 36 hours to obtain a result. Rapid tests to identify bacteria causing blood infections, and their susceptibilities to antibiotics,
provide results in eight hours or less. These rapid susceptibility tests include:
· tests that look at the direct eIect of antibiotics on bacteria (called phenotypic tests); and
· tests that look for particular genes in the bacteria to see if they are susceptible, or resistant, to an antibiotic (called genotypic tests).
What are the main results of this review?
We found six studies that involved 1638 adults with blood infections. All studies took place in specialized medical centres in high-income
countries in Europe, the USA, and East Asia.
Compared with standard tests, rapid susceptibility tests may make little to no diIerence to
· how many people died within 30 days (evidence from six studies in 1638 people);
· how long people stayed in hospital (4 studies in 1165 people); or
· how long it took for people to be given the right antibiotic to treat the infection (5 studies in 1493 people).
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Phenotypic rapid susceptibility tests may reduce the time it takes to receive the right antibiotic; but this is uncertain (evidence from 2
studies in 564 people).
Genotypic rapid susceptibility tests may make little or no diIerence to the time it takes to receive the right antibiotic (evidence from 4
studies in 1074 people).
Our confidence in the results is limited because:
· the numbers of deaths reported in the studies were too low to show an important diIerence;
· the tests used and the results from the studies varied widely;
· the studies did not include enough participants to enable firm conclusions.
Further research is likely to change these results.
How up to date is this review?
We included evidence published up to 21 October 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Rapid susceptibility methods versus standard methods versus placebo for bloodstream infection
Rapid susceptibility methods versus convention methods versus placebo
Patient or population: people with bloodstream infections
Setting: hospitals (in Europe, USA, and East Asia)
Intervention: rapid susceptibility methods
Comparison: standard of care (conventional susceptibility methods)
Anticipated absolute effects* (95% CI)Outcomes
Risk with standard
of care


























































Rapid AST with stewardship may-












Rapid AST without stewardship












We were unable to meta-analyse
the data.
Rapid AST may make no little or




























































































































































































Two studies using phenotypic susceptibility testing, reported a reduction in
time-to-appropriate antibiotic with rapid susceptibility testing.
Three studies using molecular susceptibility testing reported no difference.
Two studies using antimicrobial stewardship, reported a reduction in time-
to-appropriate antibiotic with rapid susceptibility testing.
Two studies using antimicrobial stewardship and one not using it reported
no difference. 
Two studies using rapid identification, reported a reduction in time-to-ap-
propriate antibiotic with rapid susceptibility testing. Two studies using
rapid identification and one using conventional identification plus rapid





Rapid AST may make little or no
difference to time-to-appropriate
antibiotic.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RR: risk ratio; AST: antimicrobial susceptibility testing.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded by one level for indirectness; this review pools diIerent interventions, and includes studies looking at single gene resistance traits, and those with and without
stewardship interventions.
bDowngraded by one level for imprecision. As the control group event rate was < 1%, a larger sample size than the total number of participants across trials would be required
to show a clinically important diIerence.
cDowngraded by two levels for imprecision; data were presented as means or medians rather than time-to-event data, and the standard deviations or interquartile
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B A C K G R O U N D
Description of the condition
Bloodstream infections (BSIs) can be defined as the presence
of viable bacteria or fungi in the blood that is associated
with infection (Laupland 2014). Blood culture is the reference
standard for detection of these micro-organisms in blood (Baron
2013). BSIs can be categorized as primary infections, defined as
those not secondary to an infection at another body site, and
secondary infections, where organisms are seeded from a site-
specific infection at another body site, for example a pneumonia. In
primary BSIs, organisms can enter the bloodstream through broken
skin or mucous membranes, gastrointestinal tract, or by the direct
introduction of contaminated material to the bloodstream (Reimer
1997).
Positive blood cultures do not always signify BSI, and can represent
contamination or the transient presence of bacteria in the blood
that do not cause clinical illness.
Incidence estimates for BSI vary from 166 to 204 episodes per
100,000 person-years in North America and Europe (Goto 2013).
BSI is common in sub-Saharan Africa, with a reported incidence of
574 episodes per 100,000 person-years (Deku 2019), with a higher
risk in the immunocompromised (Reddy 2010).
BSIs are oQen associated with  sepsis, defined as life-threatening
organ dysfunction due to a dysregulated host response to infection
(Rhodes 2017). Sepsis can occur in the absence of detectable
bloodstream infection. Given the complex nature of the condition
and its diagnosis, it is impossible to give precise estimates for the
global burden of disease from sepsis. However, the World Health
Organization (WHO) estimates that there are up to 31 million global
cases of sepsis and 24 million global cases of septic shock, with the
clinical conditions resulting in sepsis accounting for up to six million
deaths (WHO 2017).
Observational studies have found that inappropriate empirical
antimicrobials and delays in the initiation of appropriate antibiotic
therapy are risk factors for mortality in sepsis, with a progressive
increase in mortality with increasing delays (Ferrer 2014; Kumar
2006; Kumar 2009; Paul 2010). By necessity, the evidence for the
antibiotic treatment of sepsis is observational, as randomized
controlled trials (RCTs) would be unethical. Notwithstanding this,
sepsis guidelines emphasize early broad-spectrum antimicrobial
treatment, aimed at ensuring adequate therapy to reduce
mortality.
The use of early broad-spectrum antimicrobials has led to concerns
that people are exposed to overuse of antimicrobials, which
may result in antimicrobial resistance (Silva 2013). Guidelines
recommend that antimicrobial therapy be targeted to a specific
pathogen, if this is identified microbiologically (Rhodes 2017). The
use of targeted therapy is regarded as an important component of
antimicrobial stewardship, defined as a set of actions that promote
the responsible use of antimicrobials (Dyar 2017).
Description of the intervention
The parallel global drives to improve both the treatment of
severe infections associated with BSI  and to avoid antimicrobial
resistance have catalysed new strategies to reduce the turnaround
time between the collection of blood culture samples and the
reporting of antimicrobial susceptibility results. Purported benefits
of reduced turnaround times include reduced morbidity and
mortality, improved care, reduced healthcare costs, and reduced
antimicrobial resistance (PHE 2014).
Figure 1 depicts an overview of the conventional laboratory
diagnosis and clinical management of BSI. A clinician collects a
blood culture from a person with possible BSI, sends it to the
microbiology laboratory, and may commence empirical antibiotics.
Upon receipt, the laboratory staI load the blood cultures into an
incubator. DiIerent blood culture systems then use a variety of
methods to detect micro-organisms, and the culture bottles will
flag positive if detected. Time-to-positivity is the time between the
collection of the culture and the time at which the culture flags
positive, and is typically 12 to 24 hours.
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Figure 1.   Time to appropriate antibiotics: time to first appropriate antibiotic (from collection time of positive blood
culture to start of an antibiotic which has in vitro activity versus the identified organism)
 
AQer the blood culture flags positive, laboratory staI remove
the blood culture from the machine, and conduct a Gram stain
and microscopy. Laboratory staI then conduct subcultures to
isolate one or more organisms, and use either conventional
culture methods or rapid testing to report organism identification
and antimicrobial susceptibility. Using conventional methods, this
period is typically a further 36 hours (Maurer 2017). Based on the
report, the clinician either continues the antibiotics prescribed
earlier, or changes them. Time-to-appropriate antibiotic is the
time between the collection of the culture, and the time at which
targeted antibiotics are prescribed, according to the susceptibility
result.
The advent of mass spectrometry over the past decade has
greatly reduced the  time between the blood culture flagging
positive and the identification of the microorganism, known as
time-to-identification (Doern 2018). However, reducing the time
between a blood culture flagging positive and the availability of the
antimicrobial susceptibility results, is a more elusive target.
Antimicrobial susceptibility testing  can be grouped into the
following two main categories (Maurer 2017).
• Genotypic or molecular antimicrobial susceptibility testing:
identifies the presence or absence of a resistance gene or its
product. It can indicate to which antimicrobials the organism is
unlikely to be susceptible. Genotypic testing may be conducted
either directly on a blood sample or on an isolate.
• Rapid phenotypic antimicrobial susceptibility testing: describes
the detection of growth in the presence of an antibiotic.
In recent years,  numerous non-randomized controlled  trials
showed the  utility  of rapid susceptibility testing  to improve the
time between the identification of positive blood culture tests
and the start of eIective antimicrobial therapy. This now  ranges
between  seven  and nine hours for rapid susceptibility testing
(Pardo 2015; Pilmis 2019; Verroken 2016), compared to 25 to
36 hours for conventional testing. However, this  review will
only consider randomized controlled trials; we will not examine
observational and non-randomized studies.
For the purpose of this review,  antimicrobial
susceptibility testing may be conducted on positive blood culture
samples,  agar culture isolates following incubation, or on whole
blood specimens, drawn  directly from the person.  Rapid tests
include those that produce susceptibility results in ≤ 8 hours from
the time the blood culture flags positive. This definition relates to
the laboratory work day, during which batch testing is conducted
one or more times per eight-hour working shiQ (Buehler 2015).
How the intervention might work
Rapid antimicrobial susceptibility tests are expected to reduce the
time to clinically important results of a blood culture. This might
allow clinicians to better target therapy to a person's needs, and
thereby both improve the person's outcomes (mortality, morbidity,
length of hospital stay), and decrease  unnecessary prescribing
of broad-spectrum antibiotics, thereby, reducing the rates of
antimicrobial resistance.
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection (Review)
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Why it is important to do this review
Rapid susceptibility testing oIers a theoretical benefit to a person's
outcomes, with reduced time to targeted antibiotic therapy,
and the  potential to reduce  morbidity and mortality. It also
oIers theoretical benefit to improve antimicrobial stewardship,
and by implication,  reduce antimicrobial resistance, which is a
key concern globally. Notwithstanding the theoretical benefits,
there is uncertainty in the evidence. This Cochrane Review
may help reduce  uncertainty regarding potential benefits of this
emerging technology to a person's outcomes, and stewardship
outcomes. It may guide clinicians and laboratories in the eIective
implementation of rapid susceptibility testing, and appropriate
resource allocation to the technology. The review may also help
direct future randomized controlled trials.
O B J E C T I V E S
To assess the eIects of rapid susceptibility testing versus standard
susceptibility testing for bloodstream infections (BSIs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
People of any age with a BSI caused by any bacteria, as identified
by a positive blood culture and clinical signs of infection.
Types of interventions
Experimental intervention
Rapid antimicrobial susceptibility testing, defined as an in vitro
laboratory test to determine if an antimicrobial agent will be
active in inhibiting the growth of an organism, conducted directly
on a positive blood culture bottle, with a time-to-result ≤ 8
hours from the blood culture flagging positive. These may
include molecular antimicrobial susceptibility tests or phenotypic
antimicrobial susceptibility tests, using the definitions given above,
and may include other methods not incorporated by these
definitions, if they are identified by our search. Appendix 1 lists
interventions that may meet these criteria.
Comparator
Conventional, routine, standard antimicrobial susceptibility
techniques (automated systems, broth microdilution, manual
susceptibilities, disc diIusion or e-tests).
Types of outcome measures
Primary outcomes
• Mortality (all-cause 30-day mortality, aQer date of positive blood
culture)
• Time-to-discharge from hospital aQer positive blood culture, in
days
Secondary outcomes
Time-to-appropriate  antibiotic change to targeted or definitive
therapy, measured as time from a positive blood culture result to
a person's receipt of an antibiotic with in vitro activity against the
identified organism. This may include:
• Switching from an empirical broad- to a narrow-spectrum
antibiotic, or discontinuation of one or more antibiotics.
• Switching from an empirical narrow- to a broad-spectrum
antibiotic, or initiation of one or more antibiotics.
Search methods for identification of studies
We attempted to identify all relevant studies, regardless of
language or publication status (published, unpublished, in press,
ongoing).
Electronic searches
We searched the following databases, using the search terms and
strategy described in Appendix 2:
• Cochrane Infectious Diseases Group Specialized Register
(searched 21 October 2020);
• Central Register of Controlled Trials (CENTRAL; 2020, Issue 10),
published in the Cochrane Library (searched 21 October 2020);
• MEDLINE PubMed (1966 to 21 October 2020);
• Embase OVID (1947 to 21 October 2020); and
• LILACS BIREME (Latin American and Caribbean Health Science
Information database; 1982 to 21 October 2020).
We also searched the World Health Organization International
Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp;
searched 21 October 2020), and ClinicalTrials.gov (clinicaltrials.gov;
searched 21 October 2020), for trials in progress, using




We checked the reference lists of all studies identified by the
above methods, and of previously published reviews, and used the
'similar articles' function in PubMed to identify related studies and
references.
Researchers and organizations
In addition to the electronic searches described above, we
contacted authors of studies in progress.
Data collection and analysis
Selection of studies
Two review authors (VA and PH) independently screened references
by title and abstract, according to the inclusion criteria. We only
included studies that  reported  on at least one of our primary
outcomes. We included studies that assessed a single resistance
trait. We resolved any disagreement through discussion; we
planned to discuss disagreements with a third author, but this
was not necessary at the review stage. We obtained and assessed
the full-text of potentially eligible articles. We listed studies we
excluded aQer full-text screening and their reasons for exclusion
in the ‘Characteristics of excluded studies' table. We presented a
PRISMA flow diagram (Moher 2009).
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Data extraction and management
Two review authors (VA and PH) independently extracted
data using data extraction form. We planned to resolve any
disagreement by discussion or through a third review author
(TP), but there was no disagreement. For dichotomous outcomes
(mortality), we extracted the number of events in each arm of
the included RCTs. For all other outcomes, which were time-
to-event outcomes, we planned to extract the log hazard ratio
and its standard error from Cox proportional hazards models.
Unfortunately, none of the included studies reported time-to-event
outcomes with hazard ratios, instead reporting mean or median
averages. We contacted study authors for data, but were unable to
obtain these.
Assessment of risk of bias in included studies
Two review authors (VA and PH) independently assessed risk of bias
using the Cochrane risk of bias tool, and resolved disagreement
via discussion (Higgins 2011). We recorded the rationale used
to determine the risk of bias in each of the six domains, for
each included study. The six domains included: selection bias,
performance bias, detection bias, attrition bias, reporting bias, and
other bias.
Measures of treatment e;ect
For mortality, a dichotomous outcome, we calculated risk ratio
(RR), comparing rapid susceptibility testing to conventional
methods, with respective 95% confidence intervals (CIs).
For all other outcomes, which are time-to-event outcomes (time-to-
discharge from hospital  and  time-to-first appropriate antibiotic),
we planned to use hazard ratios (HRs) with respective 95% CIs.
However, as we were unable to extract HRs due to heterogeneity
in outcome measures, we conducted a qualitative narrative
synthesis.
Unit of analysis issues
When a trial with more than two arms contributed multiple
comparisons to a particular meta-analysis, we combined treatment
groups to avoid double-counting.
Dealing with missing data
We assessed missing data to ascertain whether it may be related to
the outcomes. We contacted trial authors for clarification, and to
request further information if missing data restricted the use of the
study in quantitative synthesis. We only analysed available studies
when data were missing at random.
Assessment of heterogeneity
We inspected the forest plots for overlapping CIs as an indicator of
heterogeneity. We assessed the Chi2 and I2 tests of heterogeneity.
For the purposes of this review, an I2 statistic value > 75% indicated
considerable heterogeneity. However, we did not consider this as a
simple ‘threshold', but instead, interpreted this in the context of the
size and direction of events, the Chi2 P value, and possible causes.
Where heterogeneity remained considerable, we did not conduct
meta-analysis.
Assessment of reporting biases
We did not generate funnel plots to assess reporting bias as
fewer than 10 studies contributed to an outcome in meta-analyses.
Data synthesis
We meta-analysed data using Review Manager 5 (Review
Manager 2020). We anticipated that we would find heterogenous
populations and interventions, so we planned to use a random-
eIects model for meta-analysis for dichotomous data.
In addition to quantitative synthesis using meta-analysis, we
conducted  planned qualitative (narrative) synthesis, based on
formal guidance. We were unable to meta-analyse time-to-event
data  due to heterogeneity in outcome measures. Therefore,
for time-to-discharge and time-to-antibiotic,  we used  textual
descriptions of studies, groupings and clusters, and tabulation
(Popay 2006).
Subgroup analysis and investigation of heterogeneity
We conducted the following  subgroup analyses:
• Genotypic compared to phenotypic techniques
• Rapid susceptibility alone or in conjunction with antimicrobial
stewardship
• Rapid susceptibility simultaneously with organism
identification or without organism identification
Sensitivity analysis
We planned to do worst-case scenario, but we did not, because it
would not have influenced our conclusions. We planned to conduct
sensitivity according to high risk of bias, but we did not encounter
any trials with high risk of bias.
Summary of findings and assessment of the certainty of the
evidence
We summarised our findings in a Summary of findings table. We
presented the following primary and secondary outcomes: all-
cause 30-day mortality aQer date of positive blood culture, time-
to-discharge from hospital aQer positive blood culture, time-to-
participant receipt of an antibiotic with in vitro activity versus
the identified organism, time-to-de-escalation: switching from
a broad- to a narrow-spectrum antibiotic or discontinuation of
one or more antibiotics, time-to-escalation: switching from a
narrow- to a broad-spectrum antibiotic or initiation of one or
more antibiotics, as outlined in the Types of outcome measures
section. We described the study settings, number of participants,
and number of studies addressing each outcome.
We assessed the certainty of evidence using the GRADE approach
(Guyatt 2011; GRADE 2014), and GRADEpro GDT soQware
(GRADEpro GDT). We rated each important outcome as described
by Balshem 2011.
• High: we are very confident that the true eIect lies close to that
of the estimate of the eIect.
• Moderate: we are moderately confident in the eIect estimate;
the true eIect is likely to be close to the estimate of the eIect.
• Low: our confidence in the eIect estimate is limited; the true
eIect may be substantially diIerent from the estimate of the
eIect.
• Very low: we have very little confidence in the eIect estimate;
the true eIect is likely to be substantially diIerent from the
estimate of eIect.
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RCTs start as high certainty of evidence, but can be downgraded if
there are valid reasons within the following five categories: risk of
bias, imprecision, inconsistency, indirectness, and publication bias
(Balshem 2011).
R E S U L T S
Description of studies
Results of the search
The search (3 December 2018, plus  an updated search on
21  October 2020) identified 3192  studies, dated from 1987.
AQer removing duplicates and screening titles and abstracts, we
identified 45  potentially relevant studies, for which we obtained
and reviewed the full text. We excluded 34  studies.  Figure 2
illustrates the search results in a PRISMA flow diagram.
 
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection (Review)










Cochrane Database of Systematic Reviews
Figure 2.   Flowchart of study selection
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Figure 2.   (Continued)
 
Authors' contacted 
We contacted three authors of eligible studies to obtain additional
data on reported outcomes and methods (Allaouchiche 1999;
Beuving 2015; Emonet 2015). In addition, we approached
two authors to request preliminary results of unpublished
studies (Banerjee 2020;  Kim 2021).  One author contacted us
back, providing us with the requested data (Banerjee 2020).
Included studies
Six randomized controlled trials (RCTs) met the inclusion criteria.
All studies were conducted in tertiary care medical centres in high
income settings. All studies included adults. Three studies included
people with both gram-positive and gram-negative BSIs (Banerjee
2015; Beuving 2015; Kim 2021). Two studies included people
with only gram-positive BSIs (Allaouchiche 1999; Emonet 2015)),
and one included people with only gram-negative BSIs (Banerjee
2020). Kim 2021 included only people with known haematological
malignancy, rather than a general hospital population.
Four studies used molecular testing platforms that detected
only a limited number of resistance genes (Allaouchiche 1999;
Banerjee 2015; Beuving 2015; Emonet 2015). Two studies used a
rapid system to determine methicillin resistance in Staphylococcus
aureus blood stream infection; Allaouchiche 1999 detected mecA/
gyrA genes, and   Emonet 2015   detected mecA/ femA genes.
Banerjee 2015 detected three antimicrobial resistance genes:
mecA for Staphylococcus spp.; vanA/B for Enterococcus spp.; and bla
KPC  for  Acinetobacter baumannii, Pseudomonas aeruginosa, or a
member of the family Enterobacteriaceae. Beuving 2015  used real-
time polymerase chain reaction (PCR) to detect the presence of
diIerent resistance genes.
Only two  studies  used a phenotypic assay that provided the
susceptibility interpretation based on a wide panel of antimicrobial
agents that were tested (Banerjee 2020; Kim 2021).  Banerjee
2020 used real-time morphokinetic cellular analysis by dark-field
microscopy, whilst Kim 2021 used a method based on microscopic
imaging analysis with microfluidic chip technology  to provide
susceptibility results.
In five  studies, rapid susceptibility testing was conducted
simultaneously with the identification of the bacteria (Banerjee
2015; Banerjee 2020; Beuving 2015; Emonet 2015; Kim 2021).
Characteristics of included studies showed reported proportion of
resistant organisms: 49% (Kim 2021), 31% (Allaouchiche 1999), 19%
(Banerjee 2020),  13% (Emonet 2015),  4% (Beuving 2015); see
Table 1. Participants on inadequate empirical antibiotic accounted
for 49% (Banerjee 2015), 28% (Emonet 2015), 26% (Beuving 2015),
25% (Allaouchiche 1999), and 16% (Kim 2021); see Table 2.
There were diIerent
approaches  to  antimicrobial  stewardship interventions  between
studies. Two studies implemented a formal antibiotic stewardship
program, combined with identification and antimicrobial
susceptibility testing results of rapid and conventional group,
including a Monday to Friday prospective audit and feedback, and
a computer-based monitoring system of antimicrobials (Banerjee
2015; Banerjee 2020). Four studies provided the results and advice
of the optimal antibiotic  (Banerjee 2015; Banerjee 2020; Beuving
2015; Kim 2021),  whereas  two studies only communicated the
results to the responsible medical team, without any antimicrobial
advice from an  infection specialist (Allaouchiche 1999;  Emonet
2015). See Characteristics of included studies.
With respect to our primary outcomes:
• Mortality (all-cause 30-day mortality, aQer date of positive
blood culture): all six studies provided data (Allaouchiche 1999;
Banerjee 2015; Banerjee 2020; Beuving 2015; Emonet 2015; Kim
2021).
• Time-to-discharge from hospital aQer positive blood culture in
days: four studies provided data (Banerjee 2015; Banerjee 2020;
Beuving 2015; Emonet 2015).
With respect to our secondary outcome:
• Time-to-appropriate antibiotic change to targeted or definitive
therapy: five  studies provided data  (Banerjee 2015; Banerjee
2020; Beuving 2015; Emonet 2015; Kim 2021).
See Characteristics of included studies for further details.
Excluded studies
We excluded 23 studies because they were not RCTs. We excluded
seven  studies because they used interventions that were not
relevant. We excluded three  studies that looked at the wrong
population, and one study that reported outcomes that were not
relevant for this review (see Characteristics of excluded studies).
Ongoing studies
We identified five  ongoing studies, but could not find further
information about when these were expected to publish (see
Characteristics of ongoing studies).
Risk of bias in included studies
See Figure 3 and Figure 4  for a summary of the risk of bias
assessments. Further details are available in the Characteristics of
included studies table.
 
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection (Review)










Cochrane Database of Systematic Reviews


























































































































































Allaouchiche 1999 ? ? ? ? ? - ?
Banerjee 2015 ? ? ? - + + +
Banerjee 2020 + + + - + + +
Beuving 2015 + + + ? + + +
Emonet 2015 + + ? ? ? + +
Kim 2021 + + + + + + ?
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Figure 4.   Risk of bias graph: a plot of the distribution of review authors' judgements across studies for each risk of
bias item.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Allocation
We judged four  studies to have low risk of selection bias, as
they adequately described generation of allocation sequences
(Banerjee 2020; Beuving 2015; Emonet 2015; Kim 2021). We judged
two studies at unclear risk of selection bias, as study authors did not
provide suIicient information (Allaouchiche 1999; Banerjee 2015).
Blinding
We judged one study at high risk of detection bias, and unclear risk
of performance bias  (Banerjee 2015). We judged three  studies at
low risk of performance bias, but unclear risk of detection bias
(Banerjee 2020; Beuving 2015; Kim 2021). Description of blinding
was unclear in two studies (Allaouchiche 1999; Emonet 2015).
Incomplete outcome data
We judged four  trials at low risk of attrition bias (Banerjee 2015;
Banerjee 2020; Beuving 2015; Kim 2021).  We considered two trials
at unclear risk of attrition bias  (Allaouchiche 1999; Emonet 2015). 
For the analysis of mortality, no data were missing. Heterogeneity
for time-to-discharge and time-to-antibiotic stopped us from
conducting a meta-analysis for these outcomes. However, the trial
authors reported no missing data for time-to-discharge and time-
to-antibiotic.
Selective reporting
We judged five trials at low risk of reporting bias (Banerjee 2015;
Banerjee 2020; Beuving 2015; Emonet 2015; Kim 2021).  We judged
one trial at high risk of reporting bias (Allaouchiche 1999).
Other potential sources of bias
We judged four trials at low risk of other potential sources of bias
(Banerjee 2015; Banerjee 2020; Beuving 2015; Emonet 2015), and
two  trials at unclear risk of other bias  (Allaouchiche 1999; Kim
2021).
E;ects of interventions
See: Summary of findings 1 Rapid susceptibility methods versus
standard methods versus placebo for bloodstream infection
Mortality
In pooled analysis, for rapid antimicrobial susceptibility testing
compared to conventional methods, there was little or  no
diIerence in mortality between groups (RR 1.10, 95% CI 0.82 to 1.46;
6 RCTs, 1638 participants); see Analysis 1.1.
Subgroup analysis
For rapid genotypic or molecular antimicrobial susceptibility
testing compared to conventional methods, there was little or
no diIerence between groups (RR 1.02, 95% CI 0.69 to  1.49; 4
RCTs, 1074 participants); see  Analysis 1.1. Two  studies  reported
phenotypic rapid susceptibility testing compared to conventional
methods, and reported little or no diIerences in mortality (RR 1.37,
95% CI 0.80 to 2.35, 2 RCTs, 564 participants); see Analysis 1.1.
For rapid susceptibility testing combined with antimicrobial
stewardship  compared to standard of care, there was little or no
diIerence between groups  (RR 1.17, 95% CI 0.81 to 1.70; 4 RCTs,
1404 participants); see Analysis 1.2.
When  rapid identification and antimicrobial susceptibility results
provided simultaneously  on the same assay was compared with
conventional method, there was little or no diIerence between
groups (RR  1.25, 95%  CI 0.77  to 2.03; 4  RCTs, 876  participants);
see Analysis 1.3.
Time-to-discharge
Four trials reported time to discharge as median times with
interquartile ranges (IQR (Banerjee 2015; Emonet 2015); N = 706),
median time with range (Beuving 2015; N = 223), and mean with
standard deviation (SD (Banerjee 2020); N = 448).
The included studies detected little or no diIerences in time-
to-discharge  between rapid antimicrobial susceptibility testing
and conventional methods (Banerjee 2015; Banerjee 2020; Beuving
2015; Emonet 2015; N = 1377). Each study reported wide ranges or
standard deviation; see Table 3
We were unable to conduct a meta-analysis for time-to-discharge
using available data. We approached authors for additional data to
conduct time-to-event analysis, but were unable to obtain this.
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Time-to-appropriate antibiotic change to targeted or
definitive therapy
Five studies reported time-to-appropriate antibiotic. Two reported
median time (Banerjee 2015; Emonet 2015; N = 706 ); three reported
mean time (Banerjee 2020; Beuving 2015; Kim 2021; N = 787 ).
Subgroup analysis
Rapid genotypic antimicrobial susceptibility testing compared to
conventional methods, showed little or no diIerences in time-to-
appropriate antibiotic (Banerjee 2015; Beuving 2015; Emonet 2015;
N = 929); see Table 4.
In subgroup analysis, rapid phenotypic susceptibility testing
compared to conventional testing  showed  reduced time-to-
appropriate antibiotic  (RR  -17.29, CI  -45.05  to  10.47; 2 RCTs, 564
participants); see Analysis 1.4.
Time-to-escalation and time-to-de-escalation of antibiotics
Participants whose culture underwent the antimicrobial
stewardship intervention in addition to rapid susceptibility testing
experienced appropriate de-escalation of antibiotics sooner (21
hours (IQR 7 to 37) versus 34 hours (IQR 21 to 55); P < 0.001),
and appropriate escalation of antibiotics sooner (5 hours (IQR 2
to 22) versus 24 hours (IQR 3 to 67); P = 0.04)  compared with
conventional testing  (Banerjee 2015; N = 617 ). Banerjee 2020 (N
= 448 ) also found that it took less time to escalate antibiotics in
the rapid susceptibility testing group combined with antimicrobial
stewardship compared with the standard testing (18.4 hours (IQR
5.8 to 72) versus 61.7 hours (IQR 30.4 to 72); P = 0.01), but time to
de-escalation showed little or no diIerence between groups.
We were  only  able to conduct a meta-analysis for time-to-
appropriate antibiotic  for the subgroup of rapid phenotypic
testing. We approached trial authors for additional data to conduct
time-to-event analysis, but were unable to obtain this.
D I S C U S S I O N
Summary of main results
Summary of findings 1 summarizes the main results.
Rapid susceptibility testing compared to conventional testing
may  make  little or no diIerence in 30-day mortality (6  RCTs,
1638 participants; low-certainty evidence).
In subgroup analysis, for rapid genotypic susceptibility testing
compared to conventional methods, there was little or no
diIerence between groups (4 RCTs, 1074 participants; low-certainty
evidence). Two  studies  (564  participants) reported phenotypic
rapid susceptibility testing compared to conventional methods,
but the 95% confidence interval crossed the line of no eIect, and
this was low-certainty evidence. In subgroup analysis, for rapid
susceptibility testing combined with antimicrobial stewardship
compared to conventional testing, there was little or no diIerence
between the groups (4  RCTs, 1404  participants; low-certainty
evidence). Rapid identification and susceptibility testing may make
no diIerence in mortality (4 RCTs, 876 participants; low-certainty
evidence).
Rapid susceptibility testing may make little or no diIerence in time-
to-discharge (4 RCTs, 1165 participants; low-certainty evidence).
Rapid genotypic susceptibility testing compared to conventional
testing may make little or no diIerence in time-to-appropriate
antibiotic (4 RCTs, 1165 participants; low-certainty evidence).
In subgroup analysis, for rapid phenotypic susceptibility testing
compared to conventional methods, may improve time-to-
appropriate antibiotic, but the evidence is uncertain  (2RCTs, 564
participants; low-certainty evidence).
Rapid susceptibility testing combined with antimicrobial
stewardship may make little or no diIerence in time-to-appropriate
antibiotic (4 RCTs, 1404 participants; low-certainty evidence). Rapid
identification along with rapid susceptibility testing  may make
little or no diIerence in time-to-appropriate antibiotic (4 RCTs, 876
participants; low-certainty evidence).
DiIerent   factors may have influenced the diIerences observed
in  time-to-appropriate  antibiotic between phenotypic and
genotypic techniques, such as providing a panel of phenotypic
susceptibilities for various antibiotics rather than having only one
resistant gene marker to indicate possible resistance to a specific
antibiotic. This may have helped in the selection of an appropriate
antibiotic in a shorter time. The implementation of antimicrobial
stewardship  and the provision of rapid identification results,
along with rapid susceptibility testing may also contribute to the
diIerences observed in time-to-appropriate antibiotic.
Overall completeness and applicability of evidence
All six  included studies were based in large academic teaching
hospitals in Europe, the USA, and East Asia. Therefore, applicability
of findings may be limited in other settings, which may have
diIerent interfaces between laboratory and clinical work. Factors
specific to the laboratory workflow and technical resources
available within clinical trials may influence the applicability of our
findings to routine clinical practice.
People with gram-positive and gram-negative bloodstream
infections (BSI) were only represented in two trials (Banerjee 2015;
Kim 2021). The rest of the studies only included people with
gram-positive BSI (Allaouchiche 1999; Beuving 2015; Emonet 2015),
or only gram-negative BSI (Banerjee 2020). In particular, Emonet
2015 had a less representative participant spectrum, as this study
focused on Staphylococcus aureus, using molecular susceptibility
testing, which targeted the microorganism S aureus, and the
detection of the mecA gene.
Banerjee 2020 and Kim 2021 showed a significant reduction in time-
to-optimal antibiotic with the implementation of rapid phenotypic
susceptibility testing and antimicrobial  stewardship program.
However, they detected no diIerences in clinical outcomes. 
Interestingly,  Banerjee 2015 did not observe significant
improvement in time-to-appropriate antibiotic,  despite  the
implementation of  an antimicrobial stewardship  program.  This
may  be due to the characteristics
of  the genotypic  rapid  susceptibility testing method used, which
looked at a restricted number of resistance genes (mecA,  vanA/
B, blaKPC) instead of the rapid phenotypic testing used in Banerjee
2020, which included  a broad panel of antimicrobial susceptibility
results. Secondly, Banerjee 2015 included gram-positive and gram-
negative bacteria and fungi, whereas Banerjee 2020, only included
gram-negative bacteria. 
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Antimicrobial resistance rates in the studied populations
did not seem to have a direct influence  on time-to-
appropriate antibiotic.  Kim 2021  found a shorter time-to-
appropriate antibiotic when using rapid  phenotypic  testing,  in
a haematological population with high bacterial resistance rates.
In contrast,  Banerjee 2015 found no improvement in time-to-
antibiotic  with rapid genotypic susceptibility, in a population
with similarly high resistance rates .
Finally, rapid  identification  may have played a role  in reducing
time-to-appropriate  antibiotic  when  combined with both rapid
susceptibility testing and antimicrobial stewardship  (Banerjee
2020; Kim 2021).  In contrast,  rapid identification and
susceptibility  without antimicrobial stewardship did not show
an improvement in time-to-antibiotics or in clinical  outcomes
(Beuving 2015; Emonet 2015). 
There are several factors that may explain why expected clinical
benefits have not been observed in this review. First, the antibiotic
resistance rate of the included studies was quite variable with a
reported low  prevalence of antibiotic-resistant bacteria  ranging
from 4% to 19% in three studies  (Beuving 2015; Emonet 2015;
Banerjee 2020),  moderate of 31%  (Allaouchiche 1999) and high
of 49% (Banerjee 2015; Kim 2021). Rapid AST may have a greater
impact if the prevalence of antimicrobial resistance increases (Kim
2021). 
Second, only around 25% (Allaouchiche 1999; Beuving 2015;
Emonet 2015; Kim 2021), and 49% (Banerjee 2015) of the
participants were on inadequate antibiotic therapy at the time
of antimicrobial susceptibility results. This probably means that
larger sample size would be needed to demonstrate diIerences in
mortality and length of stay.
Third, for many organisms, rapid  antimicrobial susceptibility
testing  may not    have  a great  impact. However,  people
with infections  caused by key pathogens such as  methicillin-
resistant  Staphylococcus aureus (MRSA), Vancomycin-
resistant Enterococcus  (VRE) or  carbapenem-resistant
Enterobacteriaceae  (CRE) may  benefit from rapid AST (Banerjee
2020; Kim 2021; Timbrook 2017).
Quality of the evidence
Certainty of the evidence
We found the evidence regarding  the mortality outcome to be
of low certainty; we considered that the data were indirect due
to  diIering  clinical interventions, including studies that looked
at single gene resistance traits, and those with and without
stewardship interventions. We also judged that the mortality data
was imprecise, as the control group event rate was < 1%. A larger
sample size than the total number of participants across trials
would be required to show a clinically important diIerence. As the
evidence pertaining to time-to-discharge and time-to-antibiotic
was variably reported using means and medians, with evidence of
wide standard deviations or interquartile ranges, we considered
that the data were imprecise, and downgraded the certainty to low.
Potential biases in the review process
The key limitation in the review process was that we were not able
to obtain time-to-event data to allow meaningful meta-analysis for
time-to-discharge and time-to-appropriate antibiotic. Such a meta-
analysis may have demonstrated a beneficial eIect.
The heterogeneity in processes used in individual studies may
represent a further potential bias. Banerjee 2015, Banerjee 2020,
and Emonet 2015 reported time-to-appropriate antibiotic as time
from Gram stain to eIective in vitro antibiotic. Beuving 2015 and
Kim 2021  defined time-to-appropriate antibiotic as time from
blood draw to administration of the appropriate antibiotic.  This
heterogeneity in the time point measurement might have had an
impact in time-to-antibiotic results, as time from blood drawing
can be less controllable but more  representative of true time-
to-appropriate antibiotic  than time from Gram stain. Notification
methods and action taken on results varied between studies.
The results were phoned directly to the responsible clinician, who
could take immediate action to change antimicrobial treatment
(Banerjee 2015; Emonet 2015), or reported to the medical
microbiologist or infectious diseases specialist, who then advised
the attending clinician of the appropriate antibiotic therapy by
telephone (Banerjee 2020; Beuving 2015; Kim 2021).
Heterogeneity in the epidemiological settings and microbiological
methods  of the trials, such as  resistance traits assessed and
bacteria targeted by the intervention, was observed between
studies.
There was heterogeneity in antimicrobial
stewardship interventions between diIerent studies. Two studies
implemented a formal antibiotic stewardship programme, and
combined it with either rapid or conventional identification
and antimicrobial susceptibility testing (Banerjee 2015; Banerjee
2020).  DiIerent studies found variable  rates of antibiotic-
resistant organisms and adequacy of empiric treatment; see Table
1; Table 2.
Agreements and disagreements with other studies or
reviews
Observational studies  assessing the clinical  impact  of rapid
antimicrobial susceptibility testing for BSIs have shown a reduction
in time-to-appropriate antibiotic, but did not report improvement
in mortality or length of stay (Ehren 2020; Huang 2013; Nicolsen
2013; Pilmis 2019).  Suzuki 2015  found  a  reduction  in  30-
day  mortality  with  rapid susceptibility testing  compared to
standard care. However, this was a non-randomized observational
prospective study, and results should be interpreted with caution.
A systematic review concluded that rapid diagnostic
testing, including organism identification, resistance mechanism
detection, or both, was associated with a decreased time-
to-eIective antibiotic, length of stay, and mortality, in the
presence of an antimicrobial stewardship program (Timbrook
2017).  However, these findings should be interpreted in view of
certain limitations: most studies were pre- and post-intervention
observational studies, only one randomized clinical trial showed
a reduction in mortality when using rapid organism identification
testing without susceptibility testing, and with no antimicrobial
stewardship intervention (Ly  2008).    This contrasts with a recent
multicentre, randomized controlled trial that showed no reduction
in patient mortality, despite using rapid identification testing alone
(MacGowan 2020).
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This is the first systematic review that exclusively considers
rapid versus standard antimicrobial susceptibility testing for blood
stream infections. Previous systematic reviews focused on the
use of rapid diagnostics, including identification techniques,
not only antimicrobial susceptibility testing  (Timbrook 2017;
Vardakas 2015). In addition, the majority of the systematic reviews
on rapid diagnostics included heterogeneous studies designs
(retrospective, prospective non-randomized trials, and prospective
randomized trials), and concluded that the evidence is insuIicient
to support the use of rapid testing in daily practice.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The theoretical benefits of rapid susceptibility testing have not
been shown in these randomized studies  to directly improve
mortality, time-to-discharge, or time-to-appropriate antibiotic, but
the certainty of evidence is low.
Implications for research
It is likely that studies to date, and this meta-analysis, do not
have large enough numbers to detect a diIerence in the most
important outcomes. Adequately  powered prospective studies
should focus on reporting the most clinically meaningful outcomes.
Studies should use time-to-event analysis rather than comparing
average times, as the latter may mask important diIerences.
Evaluation of clinical outcomes should also consider analyses
based on the number of participants who are on eIective or
ineIective antibiotic therapy before susceptibility testing results
are available. One possible outcome could be a combined time-to-
appropriate antibiotic and stewardship outcome, which includes,
for each participants, the time between which the blood culture
sample was taken and the time at which the optimal antibiotic was
administered, where optimal could be defined as the narrowest
eIective antibiotic based on antimicrobial susceptibility results.
Studies should be designed to optimise workflows to process blood
cultures, to bridge any delays from the initial draw of blood culture
samples to the final susceptibility results of blood cultures, and
ensure the results are rapidly acted on to change the person's
care. To date, rapid susceptibility testing is only available for blood
culture specimens following one or two days of incubation, rather
than directly on a person's blood sample. That delay may interfere
with the real clinical impact of rapid testing for bloodstream
infections.  Therefore, more eIorts are required to reduce the
overall blood culture incubation time.
Rapid susceptibility results should always be followed with a direct
communication of results. Studies should investigate how best
results could be communicated, to ensure appropriate changes in
antimicrobial therapy are made.
We did not conduct a cost-eIectiveness analysis, as it was not
one of our objectives for this Cochrane Review.  Nevertheless,
future studies are needed to evaluate the cost-eIectiveness of the
intervention. 
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Randomized controlled trial
Participants Adult inpatients with positive blood cultures for Staphylococcus aureus
Allaouchiche 1999 
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Included organisms: gram-positive bacteria (S.aureus)
Number of included participants: 145 (73 rapid; 72 standard care)
Interventions • Only rapid antimicrobial susceptibility testing (AST) and standard identification (ID): rapid AST
using Multiplex-polymerase chain reaction (PCR) assay; detection of mecA, gyrA resistance genes;
standard ID using cumpling factor, coagulase, heat-stable DNAse
• Standard AST and ID: standard AST using traditional overnight technique, serial dilutions in Mueller-
Hinton agar. Stardard ID cumpling factor, coagulase, heat-stable DNAse
Outcomes • Primary: survival in intensive care unit; favourable infection outcome (defined as resolution of clinical
signs, negative subsequent blood cultures)
• Secondary: length of hospital stay; duration of treatment; antibiotic cost




Notes • Prevalence of antibiotic resistance:  31% (45/145) methicillin-resistant  Staphylococcus aureus
(MRSA)
• % of participants on inadequate antibiotic: 25% (18/72) of participants in the rapid group
• Antimicrobial stewardship program: no
• Communication of results and advice of the optimal antibiotic: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk No information
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk No information
Selective reporting (re-
porting bias)
High risk Composite outcomes reported; mortality outcomes not reported by study
group; secondary outcomes not reported
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Study characteristics
Methods Randomized controlled trial; parallel group
Participants Adults and children who had positive blood cultures between August 2013 and March 2014
Included organisms: gram-positive, gram-negative, and fungi (S.aureus, CoNs, Enterococcus spp,
Streptococcus spp, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp, Candida spp)
Number of included participants: 617 (198 rapid; 212 rapid and stewardship; 207 standard of care)
Interventions • Only rapid AST and standard ID: rapid AST: rapid PBP2a testing plus FilmArray Blood Culture Identi-
fication (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5
types of fungi, and select antimicrobial-resistance genes mecA, vanA/B, blaKPC; standard ID: MALDI-
TOF
• Standard AST and ID: standard AST: rapid PBP2a testing plus conventional bacterial culture (stan-
dard Mayo practices), specific technique not specified; standard ID: MALDI-TOF
Outcomes • Primary: duration of antimicrobial therapy in the 4 days after enrolment
• Secondary: 30-day mortality; length of stay; time-to-first active antibiotic; time-to-first appropriate
de-escalation; time-to-first appropriate escalation
Setting Mayo Clinic, Roshester, Minnesota
Other relevant laboratory
techniques
MALDI-TOF (Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry)
Notes • Prevalence of antibiotic resistance: not provided
• % of participants on inadequate antibiotic: 49% (303/ 617) of all participants
• Antimicrobial stewardship program: yes. Antimicrobial stewardship interventions were in place for
all study groups, including Monday to Friday prospective audit and feedback and computer-based
monitoring system of antimicrobials.
• Communication of results and advice of the optimal antibiotic: yes
• 3 study arms: 1) standard of care. 2) rapid AST alone. 3) rapid AST and antimicrobial stewardship. For
1) and 2) results reported by telephone and by electronic medical reports in real time, with template
comments to guide antimicrobial prescribing. For 3) telephone advice at the time of results available
and over the 3 days following enrolment if a modification of antibiotic was appropriate.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Limited information; states randomization was stratified by age, ICU admis-
sion, and admission to solid organ or bone marrow transplant service
Allocation concealment
(selection bias)






Unclear risk No information
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk 'Laboratory technologists and investigators were not blinded to study arm as-
signment'.
Banerjee 2015 
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Low risk Reasons for exclusion after randomization clearly listed
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk Disclaimer that diagnostics company had no input on study design, collection,





Methods Prospective randomized controlled trial
Participants People who had a positive blood culture with Gram stain showing gram-negative bacteria, identified
during laboratory business hours; October 2017 to October 2018
Included organisms: gram-negative bacteria (E.coli, Klebsiella species, Proteus species, Enterobacter
species, Pseudomonas aeruginosa, Serratia marcescens, Citrobacter species, Acinetobacter baumanii)
Number of included participants:  448  (226 standard of care; 222 intervention group)
Interventions • Rapid AST and rapid ID: Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ Sys-
tem (AXDX) – microscopy-based method by dark-field microscopy that enables single-cell analysis for
ID and AST.  Panel of antibiotics provided for AST included: TZP, piperacillin/tazobactam; CRO, ceftri-
axone; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; ETP, ertapenem; MEM, meropenem; AMK,
amikacin; TOB, tobramycin; GEN, gentamicin; CIP, ciprofloxacin; CST, colistin; MIN, minocycline
• Standard AST and standard  ID: standard AST: broth micro-dilution or agar dilution; standard  ID:
MALDI-TOF
Outcomes • Primary: time-to-first antibiotic modification within 72 hours after randomization
• Secondary: in-hospital mortality within 30 days of randomization; length of stay in the hospital after
randomization up to 30 days




Notes • Prevalence of antibiotic resistance: 19% (84/448) resistant gram-negative bacteria
• % of participants on inadequate antibiotic: not provided
• Antimicrobial stewardship program:  yes; all participants in both arms underwent prospective audit
and feedback by institutional antimicrobial stewardship program
• Communication of results and advice of the optimal antibiotic: yes; telephone advice by the an-
timicrobial stewardship physician or pharmacist to the attending doctor, if modifications to therapy
were indicated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were assigned to each arm in a 1:1 ratio, using permuted blocks,
stratified by site
Banerjee 2020 
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Allocation concealment
(selection bias)
Low risk Randomization was conducted by laboratory technologists at the time the





Low risk The primary service was unaware of group assignment at the time of random-
ization. Antimicrobial stewardship providers were not blinded to group assign-
ment.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Once blood culture results became available, or AS interventions, or both,
were made, treating providers may have been aware of group assignment due




Low risk Reasons for exclusion after randomization clearly listed
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk Disclaimer that diagnostics company had no input on study design, collection,





Methods Randomized controlled trial
Participants People with a positive blood culture with gram-positive or aerobic gram-negative bacteria
Organisms included: gram-positive (Staphylococcus spp, Streptococcus spp, Enterococcus spp) and
gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli)
Number of included participants: 223 (114 rapid; 109 standard of care)
Interventions • Rapid AST and rapid ID: RAMAST platform (real-time-PCR) for bacterial identification and detection
of growth in the presence or absence of antibiotics
• Standard AST and ID: standard sub-culturing and BD Phoenix Automated Microbiology System
Outcomes • Primary: time-to-effective antibiotic from positive blood culture
• Secondary: 30-day mortality; length of hospital stay




Notes • Prevalence of antibiotic resistance: 4% (4/96) enterobacteriaceae
• % of participants on inadequate antibiotic: 26% of all participants
• Antimicrobial stewardship program: no formal antibiotic stewardship programme
• Communication of results and advice of the optimal antibiotic: telephone advice of the optimal
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Patients randomised separately in blocks of four patients [...] according to a
computer-generated list, which was not accessible to researchers"
Allocation concealment
(selection bias)





Low risk "Patients were unaware of the group for which they were randomised." Micro-
biologists could not be blinded due to shorter turnaround time.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 2 retrospective exclusions
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk Disclaimer that diagnostics company had no input on study design, collection,





Methods Randomized controlled trial
Participants All hospitalised adults (aged 18 years) with at least two positive bottles with gram-positive cocci in clus-
ters in the tested set of blood cultures during weekdays (7 a.m. to 3 p.m.) were screened for inclusion.
Organisms included: gram-positive bacteria (S.aureus, CoNs)
Number of included participants: 89 (48 rapid; 41 standard of care)
Interventions • Rapid AST and rapid ID: multiplex real-time PCR for identification and detection of mecA, femA re-
sistance genes
• Standard AST and ID: standard AST: disk diffusion method; ID: MALDI-TOF
Outcomes • Primary: time-to-effective antibiotic from gram-stain result
• Secondary: 28-day mortality; length of total hospital stay; length of stay in ICU
Setting Division of Infectious Diseases, Geneva University Hospital, Geneva
Other relevant laboratory
techniques
MecA resistance gene detection was only relevant to half of the participants included in the study, with
S. aureus BSI 50% (53/100)
Notes • Prevalence of antibiotic resistance: 13% (7/53) MRSA
• % of participants on inadequate antibiotic: 28% (25/89) of all participants
• Antimicrobial stewardship program: no formal antibiotic stewardship programme
Emonet 2015 
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• Communication of results and advice of the optimal antibiotic: not specified if antimicrobial ad-
vice given or only results provided. Results were reported to the attending physician and the attend-
ing infectious diseases specialist the same day they were available.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Patients were randomised using the method of randomly permuted blocks."
Allocation concealment
(selection bias)
Low risk "Allocation concealment was simply sequential, that is each new patient satis-
fying inclusion criteria was given the next number in the randomization table






Unclear risk No information
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk 2 excluded from intervention, 9 from control
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk Three authors received honoraria from diagnostics companies. Consultancies





Methods Randomized controlled trial
Participants People with haematological malignancies and at least one positive blood culture
Organisms included: gram-positive and gram-negative bacteria
Number of included participants: 116 (rapid 56; conventional 60)
Interventions • Rapid AST and rapid ID: rapid phenotypic AST in addition to standard methods. Rapid phenotypic AST
was conducted using the QMAC-dRAST (QuantaMatrix, Inc, Seoul, Republic of Korea), a method based
on microscopic imaging analysis with microfluidic chip technology, coupled with MALDI-TOF. Results
available 6 hours after Gram staining.
• Standard AST and standard ID: the MicroScan (Beckman Coulter, Inc., Atlanta, GA) for gram-positive
bacteria and the VITEK2 system (bioMerieux, Inc.) for gram-negative bacteria were automatically used
for colonies isolated on the same day
Outcomes • Primary outcome: proportion of patients receiving optimal targeted antibiotics 72 hr after blood col-
lection for culture.
Kim 2021 
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• Secondary outcomes: time-to-optimal targeted antibiotic treatment; Bacteraemia-related mortali-
ty within 30 days of randomization.





Notes • Prevalence of antibiotic resistance organisms: 49% (57/116)
• % of participants on inadequate antibiotic: 16% (19/116) of all participants
• Antimicrobial stewardship program: no formal antibiotic stewardship programme
• Communication of results and advice of the optimal antibiotic: the QMAC-dRAST machine auto-
matically conveyed the AST results to ID physicians by text message. The ID physicians contacted the
primary medical team and recommended antibiotics based on these results.
• Funding:  This work was supported by the Korean Health Technology R&D Project, Ministry of
Health & Welfare, Republic of Korea (Grants No. HI13C- 1468), Seoul National University Hospital Re-
search Fund (Grants No. 03-2018-0370) and QuantaMatrix Inc.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization method with computerized generation of random num-
bers and a block size of eight
Allocation concealment
(selection bias)
Low risk Randomization was conducted by independent microbiology laboratory per-





Low risk Blinding of participants and personnel was applied until the results of rapid
phenotypic AST were reported.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Three independent ID physicians, who were unaware of the group assign-





Low risk Reasons for exclusion after randomization clearly listed.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Unclear risk Principal investigators serve as consultants for QuantaMatrix.
Kim 2021  (Continued)
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bloos 2010 Not a randomized controlled trial (RCT); controlled observational study
Bookstaver 2017 Not a RCT; quasi-experimental cohort study
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Study Reason for exclusion
Box 2015 Not a RCT; pre-post, quasi-experimental study
Bruins 2005 Quasi-RCT; participants randomized on basis of sum of the day and month of their date of birth).
Wrong intervention, antimicrobial susceptibility over 8 hours in some participants included in the
intervention arm
Burnham 2019 Not RCT; prospective cohort study; no clinical outcomes; "theoretical opportunities to reduce the
time to antibiotic"
Buss 2018 Not a RCT; 3-arm pre/post intervention study
Cambau 2017 Not a RCT; cluster-randomized cross-over trial; no clinical outcomes
Chan, 2009 Not a RCT; cross-sectional study; no clinical outcomes, only evaluation
Clerc 2014 No relevant outcomes reported. RCT comparing standard antibiotic susceptibility testing to a Gen-
eXpert® MRSA test. Primary outcome was diagnostic accuracy.
Cosgrove 2016 Wrong intervention, not an antimicrobial susceptibility method; only rapid identification technique
was conducted (Peptide nucleic acid fluorescence in situ hybridization)
Doern 1994 Quasi-RCT; randomization method inappropriate, participants randomized on basis of first letter of
last name.
Participant group inappropriate; included participants without bloodstream infections
Draz 2013 Not a RCT; study compared laboratory performance of broad range 16s RNA PCR to conventional
methods; no clinical outcomes reported
Ehren 2019 Not RCT; quasi-experimental before-after study
Farfour 2019 Not RCT; observational study; control period versus intervention period; no clinical outcomes; eval-
uation study
Garcia-Vazquez 2013 Not a RCT. Retrospective analysis on 'randomly selected data'.
Garnier 2019 Population not relevant; not exclusively participants with bloodstream infection; other samples, in-
cluding respiratory, urinary and blood
Grijalva 2020 Not RCT; wrong study design (retrospective)
Idelevich 2015 Wrong intervention; not an antimicrobial susceptibility method; only rapid identification technique
was conducted (Multiplex PCR (mPCR) for bacterial identification directly from blood)
Jeyaratnam 2008 Not a RCT; cluster-randomized cross-over trial; no BSIs; no clinical outcomes
Kerremans 2008 Population not relevant; not exclusively participants with bloodstream infection; other samples, in-
cluding respiratory, urinary and blood
Koncelik 2016 Not a RCT; pre- and post-implementation comparison
Lucignano 2011 Not a RCT; study compared laboratory performance of rapid technique to conventional methods;
no clinical outcomes reported
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Study Reason for exclusion
Ly 2008 Wrong intervention; not an antimicrobial susceptibility method; only rapid identification technique
was conducted (peptide nucleic acid fluorescence in situ hybridization)
MacGowan 2020 Wrong intervention (only identification of organisms, not susceptibility testing)
May 2015 Population not relevant; not participants with bloodstream infection; included participants with
cutaneous abscess, and an incision and drainage procedure
Naucler 2020 wrong study design (literature review)
Pilmis 2019 Not RCT; case-control study
Rodrigues 2013 Wrong intervention; not an antimicrobial susceptibility method; only rapid identification technique
was conducted (SeptiFast)
Rodrigues 2019 Wrong Intervention; only rapid identification, no antimicrobial susceptibility testing
Roshdy 2015 Not a RCT; quasi-experimental design comparing pre- and post-intervention groups
Shang 2005 Not a RCT; study compared laboratory performance of PCR to conventional methods; no clinical
outcomes reported
Suzuki 2015 Not a RCT; clinical data were compared with those of a control period
Trenholme 1989 Wrong intervention; antimicrobial susceptibility over 8 hours in some participants included in the
intervention arm
Ward 2018 Not a RCT; study compared laboratory performance of rapid system to conventional methods; no
clinical outcomes reported
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Clinical research and trial program of early rapid pathogen identification strategy for sepsis 
Methods Randomized controlled trial
Participants 360 participants with bloodstream infections (Gram positive and Gram negative)
Interventions Carbapenem-resistant Enterobacteriaceae (CRE) screening based on blood culture and PMseqTM
rapid detection of pathogenic microorganisms based on metagenomic sequencing
Outcomes 28-day mortality; length of stay
Starting date Not yet recruiting
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Study name Genotypic versus phenotypic susceptibility testing of positive blood cultures
Methods Interventional (randomized clinical trial)
Participants 466 participants
Interventions Active comparator: Accelerate Pheno; fast ID and AST of positive blood culture bottles using the Ac-
celerate PhenoTest™ BC kit with the Accelerate Pheno™ System
Active comparator: standard of care; standard culture and AST of positive blood culture bottles
plus the Verigene® BC-GP/GN
Outcomes Mean duration of anti-pseudomonal beta-lactam therapy
Mean duration of methicillin-resistant Staphylococcus aureus (MRSA) therapy
Starting date November 2018





Study name Clinical impact of fast Phenotypic antimicrobial susceptibility testing on patients with gram-nega-
tive rod bacteraemia
Methods Randomized clinical trial; parallel assignment; open label
Participants Adults (≥ 18 years of age) hospitalized with positive blood culture due to gram-negative rod (on
Gram stain)
Interventions Intervention: diagnostic test: Accelerate Pheno
Control: standard of care
Outcomes Desirability of outcome ranking (DOOR) – composite outcome 
Starting date 30 September 2019





Study name Clinical and medico-economic evaluation of a rapid test (ePlex-BCID®, GenMark) for the diagnosis
of bacteraemia and fungaemia (HEMOFAST)
Methods Randomized controlled trial
Participants 400 participants with bacteraemia or fungaemia, or both
NCT03876990 
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Interventions Multiplex PCR: microorganism identification and detection of resistance markers
Outcomes Delay from suspicion of sepsis to optimized antibiotic or antifungal treatment
30-day mortality; length of hospital stay; antibiotic treatment duration
Starting date 20 June 2019





Study name Trial on a strategy combining rapid diagnostic testing and antimicrobial stewardship to improve
antibiotic use in patients with hospital-acquired pneumonia (SHARP)
Methods Randomized controlled trial
Participants 200 participants with hospital-acquired pneumonia
Interventions Experimental: antimicrobial stewardship + rapid diagnostic testing: Filmarray® Pneumonia Panel
(FA-PP)
Active comparator: antimicrobial stewardship
Outcomes Primary: number of days on broad-spectrum antibiotics at day 30 or end-of follow-up for 100 pa-
tients-days
Secondary: mortality; in-hospital length of stay; overall antibiotic use
Starting date 21 February 2020
Contact information Solen Kernéis, MD, PhD; +33 1 58.41.19.08; solen.kerneis@aphp.fr





D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Rapid versus standard antibiotic susceptibility testing
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Mortality (subgroups: genotypic,
phenotypic)
6 1638 Risk Ratio (M-H, Random,
95% CI)
1.10 [0.82, 1.46]
1.1.1 Genotypic AST vs standard of
care
4 1074 Risk Ratio (M-H, Random,
95% CI)
1.02 [0.69, 1.49]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1.2 Phenotypic AST vs standard of
care
2 564 Risk Ratio (M-H, Random,
95% CI)
1.37 [0.80, 2.35]
1.2 Mortality (subgroups: antimicro-
bial stewardship, without antimicro-
bial stewardship)
6 1638 Odds Ratio (M-H, Random,
95% CI)
1.12 [0.81, 1.54]
1.2.1 Rapid AST and antimicrobial
stewardship vs standard
4 1404 Odds Ratio (M-H, Random,
95% CI)
1.17 [0.81, 1.70]
1.2.2 Rapid AST alone vs standard 2 234 Odds Ratio (M-H, Random,
95% CI)
0.89 [0.35, 2.27]
1.3 Mortality (subgroups: rapid ID and
AST, AST alone
6 1638 Odds Ratio (M-H, Random,
95% CI)
1.12 [0.81, 1.54]
1.3.1 Rapid AST and ID vs standard 4 876 Odds Ratio (M-H, Random,
95% CI)
1.25 [0.77, 2.03]











Analysis 1.1.   Comparison 1: Rapid versus standard antibiotic susceptibility
testing, Outcome 1: Mortality (subgroups: genotypic, phenotypic)
Study or Subgroup







Heterogeneity: Tau² = 0.03; Chi² = 3.60, df = 3 (P = 0.31); I² = 17%
Test for overall effect: Z = 0.08 (P = 0.93)





Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 4.58, df = 5 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)






















































M-H, Random, 95% CI
1.27 [0.64 , 2.52]
0.87 [0.53 , 1.43]
1.67 [0.73 , 3.83]
0.57 [0.22 , 1.47]
1.02 [0.69 , 1.49]
1.41 [0.79 , 2.52]
1.07 [0.23 , 5.09]
1.37 [0.80 , 2.35]
1.10 [0.82 , 1.46]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours rapid Favours standard
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Analysis 1.2.   Comparison 1: Rapid versus standard antibiotic susceptibility testing, Outcome
2: Mortality (subgroups: antimicrobial stewardship, without antimicrobial stewardship)
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 2.48, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)





Heterogeneity: Tau² = 0.21; Chi² = 1.81, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 4.58, df = 5 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.66 (P = 0.51)






















































M-H, Random, 95% CI
0.86 [0.49 , 1.49]
1.47 [0.78 , 2.77]
1.77 [0.71 , 4.40]
1.08 [0.21 , 5.56]
1.17 [0.81 , 1.70]
1.34 [0.58 , 3.10]
0.51 [0.16 , 1.57]
0.89 [0.35 , 2.27]
1.12 [0.81 , 1.54]
Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours rapid Favours standard
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Analysis 1.3.   Comparison 1: Rapid versus standard antibiotic susceptibility
testing, Outcome 3: Mortality (subgroups: rapid ID and AST, AST alone
Study or Subgroup







Heterogeneity: Tau² = 0.02; Chi² = 3.26, df = 3 (P = 0.35); I² = 8%
Test for overall effect: Z = 0.89 (P = 0.37)





Heterogeneity: Tau² = 0.00; Chi² = 0.74, df = 1 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 4.58, df = 5 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.66 (P = 0.51)






















































M-H, Random, 95% CI
1.47 [0.78 , 2.77]
1.77 [0.71 , 4.40]
0.51 [0.16 , 1.57]
1.08 [0.21 , 5.56]
1.25 [0.77 , 2.03]
1.34 [0.58 , 3.10]
0.86 [0.49 , 1.49]
0.98 [0.62 , 1.56]
1.12 [0.81 , 1.54]
Odds Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours rapid Favours standard
 
 
Analysis 1.4.   Comparison 1: Rapid versus standard antibiotic susceptibility





Heterogeneity: Tau² = 329.98; Chi² = 4.77, df = 1 (P = 0.03); I² = 79%
Test for overall effect: Z = 1.22 (P = 0.22)




























IV, Random, 95% CI
-5.70 [-10.10 , -1.30]
-34.60 [-60.17 , -9.03]
-17.29 [-45.05 , 10.47]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours rapid Favours standard
 
 
A D D I T I O N A L   T A B L E S
 






 31% Staphylococcus aureus oxacillin, vancomycin
 
Staphylococcus spp oxacillin, vancomycinBanerjee 2015 49%
Enterococcus spp vancomycin
Table 1.   Rates of antibiotic-resistant organisms 
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Enterobacteriaceae  broad-spectrum – beta-lactam
(amoxicillin–clavulanic, piperacillin–tazobactam,
cefepime)
Banerjee 2020 19% Enterobacteriaceae,
Acinetobacter baumannii,
Pseudomonas aeruginosa
Broad-spectrum – beta-lactam (amoxicillin-clavu-
lanic, piperacillin-tazobactam, cefepime, cef-
tazidime, carbapenems)



































Table 1.   Rates of antibiotic-resistant organisms  (Continued)
 
 
Studies Participants on inadequate empiric antimicrobial (%)
Allaouchiche 1999 25%
Banerjee 2015 49%




Table 2.   Participants on inadequate empiric antimicrobial 
Appropriate empiric antibiotic is defined as an agent to which the blood culture organism was susceptible by antimicrobial susceptibility
testing. The time window for the initiation of empiric antibiotic varied between diIerent studies: (i) from conduct of Gram-staining: 4 to 11
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hours (Banerjee 2015); 6 to 8 hours (Emonet 2015); (ii) from blood culture drawing: 27 to 28 hours (Beuving 2015); 17 to 42 hours (Banerjee
2020); 48 to 83 hours (Kim 2021).
 
 
Average time to discharge (in days)Study
Conventional, control group Rapid, comparison group
P value
Studies using genotypic rapid susceptibility testing
Banerjee 2015 Median 8 days





















Emonet 2015 Median 27 days

















Studies using rapid AST and antimicrobial stewardship
Banerjee 2015 Median 8 days









IQR 5 to 16
N = 212
0.60

















Table 3.   Time-to-discharge 
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Studies using rapid AST without antimicrobial stewardship
Emonet 2015 Median 27 days


























Emonet 2015 Median 27 days






Studies using rapid AST (alone) without rapid ID
Banerjee 2015 Median 8 days









IQR 5 to 16
N = 212
0.60
Table 3.   Time-to-discharge  (Continued)
AST: antimicrobial susceptibility testing; IQR: interquartile range;SD: standard deviation
 
 
Average time-to-appropriate antibiotic change to targeted or definitive therapy (in
hours)
Study
Conventional or control group Rapid or comparison group
P value
Studies using genotypic rapid susceptibility testing
Banerjee 2015 Median 11 hours









IQR 2 to 20
N = 212
0.55
Beuving 2015* Mean 26.9 hours Mean 28.2 hours 0.96
Table 4.   Time-to-appropriate antibiotic 
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Emonet 2015 Median 8 hours










Mean 24.7 hours (SD 24.6)
Median 14.9 (IQR 3.3 to 41.1)
N = 226
Mean 19 hours (SD 22.9)
Median 8.6 hours (IQR 2.6 to 27.6)
N = 222
0.0125







Studies using rapid AST and antimicrobial stewardship
Banerjee 2015 Median 11 hours














Mean 24.7 hours (SD 24.6)
Median 14.9 hours (IQR 3.3 to
41.1)
N = 226
Mean 19 hours (SD 22.9)





















Studies using rapid AST without antimicrobial stewardship
Emonet 2015 Median 8 hours






Table 4.   Time-to-appropriate antibiotic  (Continued)
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Studies using rapid AST and rapid ID
Banerjee 2020
 
Mean 24.7 hours (SD 24.6)
Median 14.9 hours (IQR 3.3 to
41.1)
N = 226
Mean 19 hours (SD 22.9)












Emonet 2015 Median 8 hours
















Studies using rapid AST (alone) without rapid ID
Banerjee 2015 Median 11 hours









IQR 2 to 20
N = 212
0.55
Table 4.   Time-to-appropriate antibiotic  (Continued)
*Beuving 2015 reported time-to-appropriate antibiotic from time of blood draw; other studies reported time from positive Gram stain
AST: antimicrobial susceptibility testing; IQR: interquartile range;SD: standard deviation
 
 
A P P E N D I C E S
Appendix 1. Included interventions
Molecular: matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MS) based resistance test (MALDI-TOF MS);
fluorescence in situ hybridization with peptide nucleic acid (PNA-FISH); multiplex polymerase chain reaction (PCR); FilmArray; GenoType
blood culture; GeneXpert MRSA Cepheid; Verigene Nanosphere; BD Gene Ohm StaphSR Becton Dickinson; BDMax Staph; Eazyplex; AID;
LightMix; Check-Direct CPE; MyCycler; Sepsis FlowChip; CheckPoints; Prove-it Sepsis; B-lacta test.
Phenotypic: Accelerate Pheno; Alfred 60/AST; forward laser light scatter; qMAC-sRAST; ViteK2
Appendix 2. Detailed search strategies
MEDLINE Pubmed
#1 Search “bloodstream infection*” or “blood-stream infection*” Field: Title/Abstract
#2 Search bacteremia [Mesh]
#3 Search bacteremia or bacteraemia Field: Title/Abstract
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#4 Search “blood culture” Field: Title/Abstract
#5 Search sepsis Field: Title/Abstract
#6 Search Sepsis [Mesh]
#7 Search ((#6) or (#5) OR (#4) OR #3) or #2) or #1)
#8 Search (Streptococci or “Streptococcus pneumoniae” or “Streptococcus agalactiae” or “Streptococcus pyogenes” or “Streptococcus
viridans” or Staphylococci or “Staphylococcus aureus” or MSSA or MRSA or “Staphylococcus epidermidis” or “Staphylococcus
saprophyticus” or “Coagulase negative Staphylococci” or Enterococci or “Enterococcus faecium” or “Enterococcus faecalis” or Listeria
or “Listeria monocytogenes”or Clostridium or Fusobacterium or Peptostreptococcus or Bacillus or Haemophilus or “Haemophilus
influenzae” or Brucella or Enterobacteriaceae or “Escherichia coli” or Klebsiella or Proteus or Enterobacter or Salmonella or Citrobacter or
Pseudomonas or “Pseudomona aeruginosa” or Serratia or Acinetobacter or Stenotrophomonas or Legionella or Helicobacter or Moraxella
or Neisseria or “Neisseria meningitidis”or “Neisseria gonorrhoeae” or “Gram-negative” or “Gram-positive”) AND blood* Field: Title/Abstract
#9 Search (#7) OR #8)
#10 Search “antimicrobial susceptibility test” or “antimicrobial susceptibility testing” or “antibiotic susceptibility testing” or “susceptibility
testing” Field: Title/Abstract
#11 Search “rapid” Field: Title
#12 Search “MALDI-TOF” OR “PNA-FISH” Field: Title/Abstract
#13 Search PCR Field: Title/Abstract OR “Polymerase Chain Reaction” [Mesh]
#14 Search FilmArray or Microarray or “molecular test” or “GenoType Blood Culture” or GeneXpert or Cepheid or “Verigene Nanosphere”
Field: Title/ Abstract
#15 Search “BD Gene Ohm” or “BDMax Staph” or Eazyplex or LightMix or “Check-Direct CPE” Field: Title/ Abstract
#16 Search FlowChip or “Prove-it” or “B-lacta test” or “BetaLACTA”Field: Title/Abstract
#17 Search (“Pheno Accelerate” or “Alfred 60 AST” or “Light scattering” or “BacterioScan” or “qMAC-sRAST” or “Vitek2”) Field: Title/Abstract
#18 Search “antimicrobial stewardship” or “antimicrobial prescription” Field: Title/Abstract
#19 Search (#18 OR (17 ) OR #16) OR #15) OR #14) OR #13) OR #12) OR #11) OR #10) OR #9
#20 Search #9 AND #19
#21 Search “Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
#22 Search (random* or placebo or single-blind* or double-blind*) Field: Title/Abstract
#23 Search impact or “clinical impact” or outcomes or clinical or “clinical outcomes” or eIect Field: Title/Abstract
#24 Search evaluation or performance AND (impact* or outcome*) Field: Title/Abstract
#25 Search ((#24) OR (#23) OR #22) OR #21
#23 Search #20 AND #25
CENTRAL 2019, Issue 11
ID Search Hits
#1 “bloodstream infections”
#2 MeSH descriptor: [Sepsis] explode all trees
#3 MeSH descriptor: [Bacteremia] explode all trees
#4 bacteremia or bacteraemia
#5 “blood culture”
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#6 sepsis
#7 (Streptococci or “Streptococcus pneumoniae” or “Streptococcus agalactiae” or “Streptococcus pyogenes” or “Streptococcus viridans”
or Staphylococci or “Staphylococcus aureus” or MSSA or MRSA or “Staphylococcus epidermidis” or “Staphylococcus saprophyticus” or
“Coagulase negative Staphylococci”)
#8 (Enterococci or “Enterococcus faecium” or “Enterococcus faecalis” )
#9 Listeria
#10 Clostridium or Fusobacterium or Peptostreptococcus
#11 Bacillus or Haemophilus or “Haemophilus influenzae” or Brucella or Enterobacteriaceae or “Escherichia coli” or Klebsiella or Proteus
#12 Enterobacter or Salmonella or Citrobacter or Pseudomonas or “Pseudomona aeruginosa” or Serratia or Acinetobacter
#13 Stenotrophomonas or Legionella or Helicobacter or Moraxella or Neisseria or “Neisseria meningitidis”
#14 “Neisseria gonorrhoeae” or “Gram-negative” or “Gram-positive”
#15 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 blood
#17 #15 and #16
#18 #1 or #2 or #3 or #4 or #5 or #6 or #17
#19 “antimicrobial susceptibility test” or “antimicrobial susceptibility testing” or “antibiotic susceptibility testing” or “susceptibility
testing”
#20 rapid
#21 “MALDI-TOF” OR “PNA-FISH”
#22 PCR OR “Polymerase Chain Reaction”
#23 FilmArray or Microarray or “molecular test” or “GenoType Blood Culture” or GeneXpert or Cepheid or “Verigene Nanosphere”




#28 (“Pheno Accelerate” or “Alfred 60 AST” or “Light scattering” or “BacterioScan” or “qMAC-sRAST” or “Vitek2”)
#29 “antimicrobial stewardship” or “antimicrobial prescription”
#30 #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31 #30 and #18
Embase <1947 to 2019 Week 47>
1 bloodstream infections.mp. or bloodstream infection/
2 sepsis.mp. or sepsis/
3 staphylococcal bacteremia/ or bacteremia/ or bacteremia.mp.
4 (Streptococci or "Streptococcus pneumoniae" or "Streptococcus agalactiae" or "Streptococcus pyogenes" or "Streptococcus viridans"
or Staphylococci or "Staphylococcus aureus" or MSSA or MRSA or "Staphylococcus epidermidis" or "Staphylococcus saprophyticus" or
"Coagulase negative Staphylococci" or Enterococci or "Enterococcus faecium" or "Enterococcus faecalis").mp.
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5 (Listeria or "Listeria monocytogenes" or Clostridium or Fusobacterium or Peptostreptococcus or Bacillus or Haemophilus or
"“Haemophilus influenzae" or Brucella or Enterobacteriaceae or "Escherichia coli" or Klebsiella).mp.
6 (Proteus or Enterobacter or Salmonella or Citrobacter or Pseudomonas or "Pseudomonas aeruginosa" or Serratia or Acinetobacter
or Stenotrophomonas or Legionella or Helicobacter or Moraxella or Neisseria or "Neisseria meningitidis" or "Neisseria gonorrhoeae" or
"Gram-negative" or "Gram-positive").mp.
7 4 or 5 or 6
8 blood.mp.
9 7 and 8
10 1 or 2 or 3 or 9
11 ("antimicrobial susceptibility test* " or "antibiotic susceptibility testing" or "susceptibility testing").mp.
12 rapid.m_titl.
13 ("MALDI-TOF" or "PNA-FISH").mp.
14 (PCR or "Polymerase Chain Reaction").mp.
15 (FilmArray or Microarray or "molecular test" or "GenoType Blood Culture" or GeneXpert or Cepheid or "Verigene Nanosphere").mp.




20 ("Pheno Accelerate" or "Alfred 60 AST" or "Light scattering" or "BacterioScan" or "qMAC-sRAST" or "Vitek2").mp
21 antimicrobial stewardship.mp. or antimicrobial stewardship/
22 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23 10 and 22
24 randomized controlled trial/ or controlled clinical trial/
25 (randomized or randomised or placebo or double-blind* or single-blind*).ti. or (randomized or randomised or placebo or double-blind*
or single-blind*).ab.
26 ("clinical impact" or "clinical outcomes" or eIect).mp.
27 evaluation.mp. or evaluation study/
28 (performance adj2 (impact* or outcome*)).mp.
29 24 or 25 or 26 or 27 or 28
30 23 and 29
LILACS
"bloodstream infection$" or sepsis [Words] and "rapid test$" or PCR [Words]
Appendix 3. Definitions
• Rapid susceptibility technique: an in vitro laboratory test used to determine if an antimicrobial agent will be active in inhibiting the
growth of an organism, performed directly from a positive blood culture bottle, producing results in < 8 hours or same working day
• Phenotypic susceptibility test: the basis of phenotypic method is the minimum inhibitory concentration (MIC). Clinical MIC
breakpoints determine whether the organism is categorized as susceptible, intermediate or resistant.
• Molecular or genotypic susceptibility test: a diagnostic test that analyzes the presence or absence of resistant genes in bacteria
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• Appropriate antimicrobial therapy: antimicrobial treatment directed specifically to a micro-organism based on in vitro susceptibility
test results
• Time-to-result: the time that it takes to perform and report a laboratory susceptibility test result from the time that the sample is
received in the laboratory
• Bloodstream infection (BSI) or bacteraemia: positive blood culture result with systemic manifestations of infection
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We were unable to extract data to allow time-to-event analysis, so instead presented narrative synthesis.
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